A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

About This Trial

This early-stage study is testing a new combination of two experimental drugs to find the safest dose and learn how well the body tolerates them.
It is for people with advanced prostate cancer that has spread to the bones or lymph nodes and is no longer responding to standard hormone treatments.
Before considering this trial, you should know that you must continue your regular hormone-lowering therapy, and you cannot join if the cancer has spread to major internal organs like the liver or lungs.
Because this is a safety and dose-finding study, the main goal is to understand side effects and find the right amount of medication to give.

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.

Age Range: 18 years and older
Gender: All
Who This Trial is For: This early-stage study is testing a new combination of two experimental drugs to find the safest dose and learn how well the body tolerates them.

Full Eligibility Criteria

Inclusion Criteria

Histologically confirmed adenocarcinoma of the prostate. Primary small cell carcinoma, carcinoid tumor, neuroendocrine (NE) carcinoma, or large cell NE carcinoma arising in the prostate are not allowed; however, adenocarcinomas with NE features (for example [e.g.], immunohistochemistry [IHC] with both androgen receptor [AR]- and NE-marker positivity) are allowed
Metastatic castration-resistant prostate cancer (mCRPC) that is metastatic either to bone, any lymph node, or both without clear evidence of metastasis to visceral organs. Local-regional invasion (rectum, bladder) and bone disease with soft tissue component can be included
Prior orchiectomy or medical castration (for example, must be receiving ongoing androgen deprivation therapy with a gonadotropin-releasing hormone [GnRH] analog [agonist or antagonist] prior to the first dose of study drug and must continue this therapy throughout the treatment phase)
Prostate-specific antigen (PSA) greater than or equal to (>=) 2 nanograms per milliliters (ng/mL) at screening
Measurable or evaluable disease
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria

Toxicity related to prior anticancer therapy that has not returned to grade less than or equal to (2 weeks, and who are off corticosteroid treatment for at least 2 weeks prior to first dose of study treatment
Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments